Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 202

1.
2.

Adjuvant therapy following pancreatic resection for pancreatic duct carcinoma: a prospective randomized study.

Lygidakis NJ, Stringaris K.

Hepatogastroenterology. 1996 May-Jun;43(9):671-80.

PMID:
8799414
3.

En bloc resection for locally advanced cancer of the pancreas: is it worthwhile?

Sasson AR, Hoffman JP, Ross EA, Kagan SA, Pingpank JF, Eisenberg BL.

J Gastrointest Surg. 2002 Mar-Apr;6(2):147-57; discussion 157-8.

PMID:
11992799
4.

Pancreatic resection for pancreatic carcinoma combined with neo- and adjuvant locoregional targeting immuno-chemotherapy--a prospective randomized study.

Lygidakis NJ, Spentzouris N, Theodoracopoulos M, Dedemadi G, Gemos K, Kyriakou A.

Hepatogastroenterology. 1998 Mar-Apr;45(20):396-403.

PMID:
9638413
5.

Prognostic factors and adjuvant chemoradiation therapy after pancreaticoduodenectomy for pancreatic adenocarcinoma.

You DD, Lee HG, Heo JS, Choi SH, Choi DW.

J Gastrointest Surg. 2009 Sep;13(9):1699-706. doi: 10.1007/s11605-009-0969-5.

PMID:
19582512
6.

Mono-bloc total spleno-pancreaticoduodenectomy for pancreatic head carcinoma with portal-mesenteric venous invasion. A prospective randomized study.

Lygidakis NJ, Singh G, Bardaxoglou E, Dedemadi G, Sgourakis G, Nestoridis J, Malliotakis A, Pedonomou M, Solomou EK, Safioleas M, Alamani M, Grigorakos L, Merikas EM.

Hepatogastroenterology. 2004 Mar-Apr;51(56):427-33.

PMID:
15086174
7.

The lymph node ratio is the strongest prognostic factor after resection of pancreatic cancer.

Riediger H, Keck T, Wellner U, zur Hausen A, Adam U, Hopt UT, Makowiec F.

J Gastrointest Surg. 2009 Jul;13(7):1337-44. doi: 10.1007/s11605-009-0919-2.

PMID:
19418101
8.
9.

Randomized trial of adjuvant therapy in colon carcinoma: 10-year results of NSABP protocol C-01.

Smith RE, Colangelo L, Wieand HS, Begovic M, Wolmark N.

J Natl Cancer Inst. 2004 Aug 4;96(15):1128-32.

10.

Pancreatic head carcinoma: is pancreatic resection indicated for patients with stage III pancreatic duct cancer?.

Lygidakis NJ, Papadopoulou P.

Hepatogastroenterology. 1995 Sep-Oct;42(5):587-96.

PMID:
8751219
11.

Adjuvant intra-arterial chemotherapy and radiotherapy versus surgery alone in resectable pancreatic and periampullary cancer: a prospective randomized controlled trial.

Morak MJ, van der Gaast A, Incrocci L, van Dekken H, Hermans JJ, Jeekel J, Hop WC, Kazemier G, van Eijck CH.

Ann Surg. 2008 Dec;248(6):1031-41. doi: 10.1097/SLA.0b013e318190c53e.

PMID:
19092348
12.

Intensified adjuvant combined modality therapy for resected periampullary adenocarcinoma: acceptable toxicity and suggestion of improved 1-year disease-free survival.

Chakravarthy A, Abrams RA, Yeo CJ, Korman LT, Donehower RC, Hruban RH, Zahurek ML, Grochow LB, O'Reilly S, Hurwitz H, Jaffee EM, Lillemoe KD, Cameron JL.

Int J Radiat Oncol Biol Phys. 2000 Nov 1;48(4):1089-96.

PMID:
11072167
13.

Adjuvant interferon-based chemoradiation followed by gemcitabine for resected pancreatic adenocarcinoma: a single-institution phase II study.

Linehan DC, Tan MC, Strasberg SM, Drebin JA, Hawkins WG, Picus J, Myerson RJ, Malyapa RS, Hull M, Trinkaus K, Tan BR Jr.

Ann Surg. 2008 Aug;248(2):145-51. doi: 10.1097/SLA.0b013e318181e4e9.

PMID:
18650621
14.

Effect of multiple-phase regional intra-arterial infusion chemotherapy on patients with resectable pancreatic head adenocarcinoma.

Jin C, Yao L, Long J, Fu DL, Yu XJ, Xu J, Yang F, Ni QX.

Chin Med J (Engl). 2009 Feb 5;122(3):284-90.

PMID:
19236805
15.

Sequential and/or concurrent hypofractionated radiotherapy and concurrent chemotherapy in neoadjuvant treatment of advanced adenocarcinoma of the pancreas. Outcome and patterns of failure.

Zimmermann FB, Schuhmacher C, Lersch C, Bernhardt B, Pickel P, Siewert JR, Molls M, Jeremic B.

Hepatogastroenterology. 2004 Nov-Dec;51(60):1842-6.

PMID:
15532839
16.

En bloc vascular resection for locally advanced pancreatic malignancies infiltrating major blood vessels: perioperative outcome and long-term survival in 136 patients.

Yekebas EF, Bogoevski D, Cataldegirmen G, Kunze C, Marx A, Vashist YK, Schurr PG, Liebl L, Thieltges S, Gawad KA, Schneider C, Izbicki JR.

Ann Surg. 2008 Feb;247(2):300-9. doi: 10.1097/SLA.0b013e31815aab22.

PMID:
18216537
17.

Preoperative chemoradiation for adenocarcinoma of the pancreas and duodenum.

Coia L, Hoffman J, Scher R, Weese J, Solin L, Weiner L, Eisenberg B, Paul A, Hanks G.

Int J Radiat Oncol Biol Phys. 1994 Aug 30;30(1):161-7.

PMID:
8083109
18.

Downstaging in pancreatic cancer: a matched analysis of patients resected following systemic treatment of initially locally unresectable disease.

Bickenbach KA, Gonen M, Tang LH, O'Reilly E, Goodman K, Brennan MF, D'Angelica MI, Dematteo RP, Fong Y, Jarnagin WR, Allen PJ.

Ann Surg Oncol. 2012 May;19(5):1663-9. doi: 10.1245/s10434-011-2156-7.

PMID:
22130621
19.

Multimodality therapy for pancreatic cancer in the U.S. : utilization, outcomes, and the effect of hospital volume.

Bilimoria KY, Bentrem DJ, Ko CY, Tomlinson JS, Stewart AK, Winchester DP, Talamonti MS.

Cancer. 2007 Sep 15;110(6):1227-34.

20.

Long-term effects of multimodal treatment for patients with resectable carcinoma of the pancreas.

Okabayashi T, Nishimori I, Nishioka A, Yamashita K, Sugimoto T, Dabanaka K, Maeda H, Kohsaki T, Ogawa Y, Kobayashi M, Onishi S, Hanazaki K.

Oncol Rep. 2008 Sep;20(3):651-6.

PMID:
18695919
Items per page

Supplemental Content

Support Center